SMAD2 and neoplasm: Among the 294 tumours for which gene dosage data (Smad2, Smad4 and DCC) were available, 167 tumours (57%) showed heterozygous loss of Smad4 (Boulay et al, 1999), and 73 out of 167 samples were randomly chosen for mutation analysis.